Terms: = Prostate cancer AND TMPRSS2, PRSS10, 7113, ENSG00000184012, O15393 AND Staging
8 results:
1. Differences in prostate cancer Transcriptomes by Age at Diagnosis: Are Primary Tumors from Older Men Inherently Different?
Zhou CD; Pettersson A; Plym A; Tyekucheva S; Penney KL; Sesso HD; Kantoff PW; Mucci LA; Stopsack KH
Cancer Prev Res (Phila); 2022 Dec; 15(12):815-825. PubMed ID: 36125434
[TBL] [Abstract] [Full Text] [Related]
2. KLK3 and tmprss2 for molecular lymph-node staging in prostate cancer patients undergoing radical prostatectomy.
Lunger L; Retz M; Bandur M; Souchay M; Vitzthum E; Jäger M; Weirich G; Schuster T; Autenrieth M; Kübler H; Maurer T; Thalgott M; Herkommer K; Koll F; Gschwend JE; Nawroth R; Heck MM
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):362-369. PubMed ID: 32978525
[TBL] [Abstract] [Full Text] [Related]
3. prostate Specific Antigen as a Tumor Marker in prostate cancer: Biochemical and Clinical Aspects.
Salman JW; Schoots IG; Carlsson SV; Jenster G; Roobol MJ
Adv Exp Med Biol; 2015; 867():93-114. PubMed ID: 26530362
[TBL] [Abstract] [Full Text] [Related]
4. Future prospects in the diagnosis and management of localized prostate cancer.
Tefekli A; Tunc M
ScientificWorldJournal; 2013; 2013():347263. PubMed ID: 24163619
[TBL] [Abstract] [Full Text] [Related]
5. Expressed prostatic secretion biomarkers improve stratification of NCCN active surveillance candidates: performance of secretion capacity and tmprss2:ERG models.
Whelan C; Kawachi M; Smith DD; Linehan J; Babilonia G; Mejia R; Wilson T; Smith SS
J Urol; 2014 Jan; 191(1):220-6. PubMed ID: 23669563
[TBL] [Abstract] [Full Text] [Related]
6. Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the tmprss2-ERG fusion gene.
Ribeiro FR; Paulo P; Costa VL; Barros-Silva JD; Ramalho-Carvalho J; Jerónimo C; Henrique R; Lind GE; Skotheim RI; Lothe RA; Teixeira MR
PLoS One; 2011; 6(7):e22317. PubMed ID: 21814574
[TBL] [Abstract] [Full Text] [Related]
7. Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer.
Ishkanian AS; Zafarana G; Thoms J; Bristow RG
Acta Oncol; 2010 Oct; 49(7):888-94. PubMed ID: 20590366
[TBL] [Abstract] [Full Text] [Related]
8. Epigenetic alterations in human prostate cancers.
Nelson WG; De Marzo AM; Yegnasubramanian S
Endocrinology; 2009 Sep; 150(9):3991-4002. PubMed ID: 19520778
[TBL] [Abstract] [Full Text] [Related]
